PubMed Health⌕ Search

Biomedical subjects

M Galloway

Publications and source records attributed to M Galloway.

40 records · Page 3Linked to original sources
PubMed1986

In vitro and clinical studies on intravenous feeding mixtures comprising fat emulsion, amino acid and electrolytes.

This paper describes the effect of the amino acid mixture Freamine II on the physical stability of Intralipid fat emulsion. The amino acid-fat emulsion mixture was also administered to patients requiring intravenous nutrition and its clinical and biochemical effects were assessed. The amino acid-fat emulsion mixture was stable on storage for 48 hours as judged by flocculation and particle growth measurements made in the presence of 20 mmol/1 monovalent cations at 2 mmol/1 diavalent cations. Long-term storage of mixtures containing Freamine II is not recommended because of an interaction between the emulsifier and the amino acids. In a small open trial patients maintained their serum albumin concentrations. There was no evidence of impaired pulmonary function even in those subjects with impaired fat clearance.

Journal Article↗
PubMed1986

Studies on fat emulsions in combined nutrition solutions.

The effect of added Aminoplex, Glucoplex, nutrient additives and calcium chloride on the stability of a fat emulsion (Intralipid) has been examined. The conclusions are as follows: Aminoplex and Glucoplex do not cause a decrease in the physical stability of mixed systems that contain fat droplets stored at room temperature for at least 7 days. The mixed systems are stable even in the presence of high electrolyte loads (greater than 600 mmol litre-1 expressed in terms of monovalent cation). The amino acids in Aminoplex could be having a stabilizing effect on the emulsion system by the adsorption of components to the oil/water interface.

Drug Stability↗
PubMed1983

Chronic inflammatory bowel disease, deep-venous thrombosis and antithrombin activity.

Of 34 patients with chronic inflammatory bowel disease (CIBD), 4 developed well-documented episodes of deep-venous thrombosis. All 4 patients had active disease at the time of thrombosis. This group was studied to determine if the tendency to deep-venous thrombosis in patients with CIBD was associated with reduced antithrombin activity by measuring the concentration of three thrombin inhibitors, antithrombin III (AT III), alpha 2-macroglobulin (alpha 2 M) and alpha 1-antitrypsin. 2 patients had low AT III levels and 10 had low alpha 2 M levels. 2 patients who developed deep-venous thrombosis had significantly low levels of both AT III and alpha 2 M. It is suggested that in patients with diseases predisposing to thrombosis and associated with low AT III levels, the measurement of alpha 2 M in addition to AT III may predict those particularly at risk.

Antithrombin III↗